162 related articles for article (PubMed ID: 25016371)
1. New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni.
Guglielmo S; Cortese D; Vottero F; Rolando B; Kommer VP; Williams DL; Fruttero R; Gasco A
Eur J Med Chem; 2014 Sep; 84():135-45. PubMed ID: 25016371
[TBL] [Abstract][Full Text] [Related]
2. Identification of oxadiazoles as new drug leads for the control of schistosomiasis.
Sayed AA; Simeonov A; Thomas CJ; Inglese J; Austin CP; Williams DL
Nat Med; 2008 Apr; 14(4):407-12. PubMed ID: 18345010
[TBL] [Abstract][Full Text] [Related]
3. Molecular docking to explore the possible binding mode of potential inhibitors of thioredoxin glutathione reductase.
Huang J; Hua W; Li J; Hua Z
Mol Med Rep; 2015 Oct; 12(4):5787-95. PubMed ID: 26239395
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of oxadiazole-2-oxide derivatives as potential drug candidates for schistosomiasis targeting SjTGR.
Li G; Guo Q; Feng C; Chen H; Zhao W; Li S; Hong Y; Sun D
Parasit Vectors; 2021 Apr; 14(1):225. PubMed ID: 33902686
[TBL] [Abstract][Full Text] [Related]
5. Thioredoxin glutathione reductase as a novel drug target: evidence from Schistosoma japonicum.
Song L; Li J; Xie S; Qian C; Wang J; Zhang W; Yin X; Hua Z; Yu C
PLoS One; 2012; 7(2):e31456. PubMed ID: 22384025
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Lead Compounds Targeting the Selenoprotein Thioredoxin Glutathione Reductase for Treatment of Schistosomiasis.
Lyu H; Petukhov PA; Banta PR; Jadhav A; Lea WA; Cheng Q; Arnér ESJ; Simeonov A; Thatcher GRJ; Angelucci F; Williams DL
ACS Infect Dis; 2020 Mar; 6(3):393-405. PubMed ID: 31939288
[TBL] [Abstract][Full Text] [Related]
7. Macromolecular bases of antischistosomal therapy.
Angelucci F; Miele AE; Boumis G; Brunori M; Dimastrogiovanni D; Bellelli A
Curr Top Med Chem; 2011; 11(16):2012-28. PubMed ID: 21619508
[TBL] [Abstract][Full Text] [Related]
8. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target.
Kuntz AN; Davioud-Charvet E; Sayed AA; Califf LL; Dessolin J; Arnér ES; Williams DL
PLoS Med; 2007 Jun; 4(6):e206. PubMed ID: 17579510
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of 1,4-naphthoquinone ether derivatives as SmTGR inhibitors and new anti-schistosomal drugs.
Johann L; Belorgey D; Huang HH; Day L; Chessé M; Becker K; Williams DL; Davioud-Charvet E
FEBS J; 2015 Aug; 282(16):3199-217. PubMed ID: 26111549
[TBL] [Abstract][Full Text] [Related]
10. Fragment-Based Discovery of a Regulatory Site in Thioredoxin Glutathione Reductase Acting as "Doorstop" for NADPH Entry.
Silvestri I; Lyu H; Fata F; Boumis G; Miele AE; Ardini M; Ippoliti R; Bellelli A; Jadhav A; Lea WA; Simeonov A; Cheng Q; Arnér ESJ; Thatcher GRJ; Petukhov PA; Williams DL; Angelucci F
ACS Chem Biol; 2018 Aug; 13(8):2190-2202. PubMed ID: 29800515
[TBL] [Abstract][Full Text] [Related]
11. Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis.
Rai G; Sayed AA; Lea WA; Luecke HF; Chakrapani H; Prast-Nielsen S; Jadhav A; Leister W; Shen M; Inglese J; Austin CP; Keefer L; Arnér ES; Simeonov A; Maloney DJ; Williams DL; Thomas CJ
J Med Chem; 2009 Oct; 52(20):6474-83. PubMed ID: 19761212
[TBL] [Abstract][Full Text] [Related]
12. Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade.
Simeonov A; Jadhav A; Sayed AA; Wang Y; Nelson ME; Thomas CJ; Inglese J; Williams DL; Austin CP
PLoS Negl Trop Dis; 2008 Jan; 2(1):e127. PubMed ID: 18235848
[TBL] [Abstract][Full Text] [Related]
13. Oxadiazole-2-oxides may have other functional targets, in addition to SjTGR, through which they cause mortality in Schistosoma japonicum.
Song LJ; Luo H; Fan WH; Wang GP; Yin XR; Shen S; Wang J; Jin Y; Zhang W; Gao H; Liu Q; Wang WL; Feng B; Yu CX
Parasit Vectors; 2016 Jan; 9():26. PubMed ID: 26791563
[TBL] [Abstract][Full Text] [Related]
14. Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
da Silva VBR; Campos BRKL; de Oliveira JF; Decout JL; do Carmo Alves de Lima M
Bioorg Med Chem; 2017 Jul; 25(13):3259-3277. PubMed ID: 28495384
[TBL] [Abstract][Full Text] [Related]
15.
Oyinloye BE; Shamaki DE; Agbebi EA; Onikanni SA; Ubah CS; Aruleba RT; Dao TNP; Owolabi OV; Idowu OT; Mathenjwa-Goqo MS; Esan DT; Ajiboye BO; Omotuyi OI
Molecules; 2024 Apr; 29(9):. PubMed ID: 38731401
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the antioxidant defence in different developmental stages of Schistosoma mansoni by praziquantel and artemether.
El-Bassiouni EA; Helmy MH; Saad EI; El-Nabi Kamel MA; Abdel-Meguid E; Hussein HS
Br J Biomed Sci; 2007; 64(4):168-74. PubMed ID: 18236739
[TBL] [Abstract][Full Text] [Related]
17. MCR synthesis of praziquantel derivatives.
Liu H; William S; Herdtweck E; Botros S; Dömling A
Chem Biol Drug Des; 2012 Apr; 79(4):470-7. PubMed ID: 22151001
[TBL] [Abstract][Full Text] [Related]
18. High-throughput screening against thioredoxin glutathione reductase identifies novel inhibitors with potential therapeutic value for schistosomiasis.
Li T; Ziniel PD; He PQ; Kommer VP; Crowther GJ; He M; Liu Q; Van Voorhis WC; Williams DL; Wang MW
Infect Dis Poverty; 2015 Aug; 4():40. PubMed ID: 26341081
[TBL] [Abstract][Full Text] [Related]
19. Schistosoma mansoni alter transcription of immunomodulatory gene products following in vivo praziquantel exposure.
McCusker P; Rohr CM; Chan JD
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009200. PubMed ID: 33657133
[TBL] [Abstract][Full Text] [Related]
20. Development of chiral praziquantel analogues as potential drug candidates with activity to juvenile Schistosoma japonicum.
Zheng Y; Dong L; Hu C; Zhao B; Yang C; Xia C; Sun D
Bioorg Med Chem Lett; 2014 Sep; 24(17):4223-6. PubMed ID: 25127102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
